# US 2024/0002860 A1 · SARS-CoV-2 SPIKE GLYCOPROTEIN-BINDING NUCLEIC ACID MOLECULE, SARS-CoV-2 DETECTION SENSOR, SARS-CoV-2 DETECTION REAGENT, SARS-CoV-2 DETECTION METHOD, AND SARS-CoV-2 VIRUS DEACTIVATOR

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002860 A1
- Document ID: US20240002860A1
- Status: Published application
- Kind: A1
- Application number: 18/038,955
- Filed: 2021-09-22
- Published: 2024-01-04
- Earliest claimed: 2020-11-30
- Assignees: NEC Solution Innovators, Ltd.
- Applicants: NEC Solution Innovators, Ltd.
- Inventors: Hirotaka Minagawa; Tomoko Fujita; Shintaro Kato; Asumi Inaguma; Katsunori Horii
- Web page: https://patentgrep.com/patent/US20240002860A1

## CPC

- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- G01N 33/56983: {Viruses}
- C12N 2310/16: Aptamers
- C12N 2310/335: Modified T or U
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

An example object of the invention is to provide a binding nucleic acid molecule capable of specifically binding to a SARS-CoV-2 spike glycoprotein. A SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to an example aspect of the invention includes: any of the following polynucleotides (a), and (b): (a) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 7 or a partial sequence of any of the base sequences of SEQ ID NOs: 1 to 7; (b) a polynucleotide consisting of a base sequence having 80% or more identity to any base sequence of the polynucleotide (a), and binding to a SARS-CoV-2 spike glycoprotein:

## Claims

### Claim 1

A SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule, comprising:
any of the following polynucleotides (a), (b), (c) and (d):
(a) a polynucleotide consisting of any of base sequences of SEQ ID NOs: 1 to 7 or a partial sequence of any of the base sequences of SEQ ID NOs: 1 to 7;
(b) a polynucleotide consisting of a base sequence having 80% or more identity to any base sequence of the polynucleotide (a), and binding to a SARS-CoV-2 spike glycoprotein;
(c) a polynucleotide consisting of a base sequence complementary to a polynucleotide that hybridizes to a polynucleotide consisting of any base sequence of the polynucleotide (a) under a stringent condition, and binding to a SARS-CoV-2 spike glycoprotein; and
(d) a polynucleotide consisting of a base sequence obtained by deletion, substitution, insertion, and/or addition of one to several bases in any base sequence of the polynucleotide (a), and binding to a SARS-CoV-2 spike glycoprotein:
SEQ ID NO: 1:
GGTATGTCTCCGCCACTGAAATCCGTGCCTAATCTCACCCCACGGAATTC
ATGGCAAAGCCGAGGTGTCTTGTATTC;
SEQ ID NO: 2:
GGTATGTCTCCGCCACTGAAATCTAATCTCACATTGTAAGCAAAGGAGAA
TAAGCAAAGCCGAGGTGTCTTGTATTC;
SEQ ID NO: 3:
GGTATGTCTCCGCCACTGAAATCCCTGACCGCTGACCAAATCTCAGTTGC
AGATGCAAAGCCGAGGTGTCTTGTATTC;
SEQ ID NO: 4:
GGTATGTCTCCGCCACTGAAATCTTGTCCCCTAATAGGTTCCGACTGACA
AGTGCAAAGCCGAGGTGTCTTGTATTC;
SEQ ID NO: 5:
GGTTTAGCCCTCGACTCCAAATGTGCACTCTCCCGGTATCCCTAATCTCA
CCCGATACCGTTGATGTGCTGCCAATAC;
SEQ ID NO: 6:
GGTTTAGCCCTCGACTCCAAATGACATGAGCCAGGTGCATCTTGAACGTC
ATAGATACCGTTGATGTGCTGCCAATAC;
SEQ ID NO: 7:
GGTTTAGCCCTCGACTCCAAATGTGCTGATACTCGGTATCCCTAATCTCA
CCCGATACCGTTGATGTGCTGCCAATAC.

### Claim 2 (depends on 1)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1, wherein
the partial sequence of the base sequence of SEQ ID NO: 1 is the base sequence of SEQ ID NO: 8,
the partial sequence of the base sequence of SEQ ID NO: 2 is the base sequence of SEQ ID NO: 9,
the partial sequence of the base sequence of SEQ ID NO: 3 is the base sequence of SEQ ID NO: 10,
the partial sequence of the base sequence of SEQ ID NO: 5 is the base sequence of SEQ ID NO: 11,
the partial sequence of the base sequence of SEQ ID NO: 6 is the base sequence of SEQ ID NO: 12, or
the partial sequence of the base sequence of SEQ ID NO: 7 is the base sequence of SEQ ID NO: 13:
SEQ ID NO: 8:
CCACTGAAATCCGTGCCTAATCTCACCCCACGGAATTCATGG;
SEQ ID NO: 9:
TCCGCCACTGAAATCTAATCTCACATTGTAAGCAAAGGAGAATAA;
SEQ ID NO: 10:
CCACTGAAATCCCTGACCGCTGACCAAATCTCAGTGCAGAT;
SEQ ID NO: 11:
TGTGCACTCTCCCGGTATCCCTAATCTCACCCGATACC;
SEQ ID NO: 12:
TGACATGAGCCAGGTGCATCTTGAACGTCATAGATACCGTTGATGTGCTG;
SEQ ID NO: 13:
GCTGATACTCGGTATCCCTAATCTCACCCGATACCG.

### Claim 3 (depends on 1)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1, wherein
the polynucleotide (b) is the following polynucleotide (b1): (b1) a polynucleotide consisting of a base sequence having 80% or more identity to any base sequence of the polynucleotide (a), comprising any of the base sequences of SEQ ID NOs: 8 to 13, and binding to a SARS-CoV-2 spike glycoprotein.

### Claim 4 (depends on 1)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1, wherein
the polynucleotide (d) is the following polynucleotide (d1):
(d1) a polynucleotide consisting of a base sequence obtained by deletion, substitution, insertion, and/or addition of one to several bases in any base sequence of the polynucleotide (a), comprising any of the base sequences of SEQ ID NOs: 8 to 13, and binding to a SARS-CoV-2 spike glycoprotein.

### Claim 5 (depends on 1)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1, wherein
the binding nucleic acid molecule comprises a modified base being a base modified with a modifying group.

### Claim 6 (depends on 5)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 5, wherein
the modified base is a modified thymine base being a thymine base modified with a modifying group.

### Claim 7 (depends on 6)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 6, wherein
the modified thymine base is a modified thymine base represented by the following formula (1):

### Claim 8 (depends on 5)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 5, wherein
underlined thymine bases in the base sequences of SEQ ID Nos: 1 to 13 in the polynucleotide are modified bases.

### Claim 9 (depends on 1)

The SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1, wherein
the polynucleotide is a DNA.

### Claim 10 (depends on 1)

A SARS-CoV-2 detection sensor, comprising:
the SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1.

### Claim 11 (depends on 1)

A SARS-CoV-2 detection reagent, comprising:
the SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1.

### Claim 12 (depends on 1)

A method for detecting SARS-CoV-2, comprising:
detecting a SARS-CoV-2 spike glycoprotein in the sample by bringing a sample into contact with a nucleic acid molecule; wherein
the nucleic acid molecule is the SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1, and
in the detecting, the SARS-CoV-2 spike glycoprotein in the sample is bonded to the nucleic acid molecule to detect the SARS-CoV-2 spike glycoprotein in the sample.

### Claim 13 (depends on 12)

The method for detecting SARS-CoV-2 according to claim 12, wherein
the sample is at least one selected from the group consisting of aerosols, saliva, urine, plasma, and serum.

### Claim 14 (depends on 1)

A SARS-CoV-2 virus deactivator, comprising:
the SARS-CoV-2 spike glycoprotein-binding nucleic acid molecule according to claim 1.
